P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

• E. C. Piccione,
• A. Belousov,
• H. Hamidi,
• C. Carlo-Stella,
• M. Dickinson,
• F. Morschhauser,
• L. Lundberg,
• K. Humphrey,
• S. Tracy,
• M. Hutchings

Affiliations

E. C. Piccione

1 Genentech, Inc., South San Francisco, CA, United States of America

A. Belousov

2 F. Hoffmann-La Roche Ltd, Basel, Switzerland

H. Hamidi

1 Genentech, Inc., South San Francisco, CA, United States of America

C. Carlo-Stella

3 Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

M. Dickinson

4 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia

F. Morschhauser

5 Hôpital Claude Huriez and CHU de Lille, Lille, France

L. Lundberg

2 F. Hoffmann-La Roche Ltd, Basel, Switzerland

K. Humphrey

6 Roche Products Ltd, Welwyn Garden City, United Kingdom

S. Tracy

1 Genentech, Inc., South San Francisco, CA, United States of America

M. Hutchings

7 Rigshospitalet, Copenhagen, Denmark